Firefly Neuroscience, Inc. (AIFF) - Total Liabilities
Based on the latest financial reports, Firefly Neuroscience, Inc. (AIFF) has total liabilities worth $2.75 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Firefly Neuroscience, Inc. (AIFF) cash conversion ratio to assess how effectively this company generates cash.
Firefly Neuroscience, Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how Firefly Neuroscience, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See net assets of Firefly Neuroscience, Inc. for net asset value and shareholders' equity analysis.
Firefly Neuroscience, Inc. Competitors by Total Liabilities
The table below lists competitors of Firefly Neuroscience, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rubicon Organics Inc
V:ROMJ
|
Canada | CA$19.46 Million |
|
Murray International Trust
LSE:MYI
|
UK | GBX112.39 Million |
|
Aasen Sparebank
OL:AASB
|
Norway | Nkr6.22 Billion |
|
Reservoir Link Energy Bhd
KLSE:0219
|
Malaysia | RM93.24 Million |
|
Przedsiebiorstwo Produkcyjno Handlowe Kompap SA
WAR:KMP
|
Poland | zł38.56 Million |
|
ECA
KLSE:0267
|
Malaysia | RM24.03 Million |
|
Castec Korea Co Ltd
KQ:071850
|
Korea | ₩127.20 Billion |
|
Neuroscientific Biopharmaceuticals Ltd
AU:NSB
|
Australia | AU$149.22K |
Liability Composition Analysis (2020–2024)
This chart breaks down Firefly Neuroscience, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Firefly Neuroscience, Inc. (AIFF) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Firefly Neuroscience, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Firefly Neuroscience, Inc. (2020–2024)
The table below shows the annual total liabilities of Firefly Neuroscience, Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.98 Million | +96.52% |
| 2023-12-31 | $2.53 Million | +12.73% |
| 2022-12-31 | $2.25 Million | -43.38% |
| 2021-12-31 | $3.97 Million | +83.63% |
| 2020-12-31 | $2.16 Million | -- |
About Firefly Neuroscience, Inc.
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depres… Read more